# US 2025/0367201 A1 · Combination therapy for treating abnormal cell growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367201 A1
- Document ID: US20250367201A1
- Status: Published application
- Kind: A1
- Application number: 18/871,048
- Filed: 2023-05-31
- Published: 2025-12-04
- Earliest claimed: 2022-06-03
- Assignees: Verastem, Inc.
- Applicants: Verastem, Inc.
- Inventors: SILVIA COMA; JONATHAN A. PACHTER
- Web page: https://patentgrep.com/patent/US20250367201A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates, in part, to methods, compounds, and compositions of a KRAS G12D inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a dual RAF/MEK inhibitor and an effective amount of a KRAS G12D inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is identified as having a KRAS G12D mutation.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the dual RAF/MEK inhibitor is a compound of formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the dual RAF/MEK inhibitor is a compound of formula (I):

### Claim 5 (depends on 3)

The method of claim 3, wherein the dual RAF/MEK inhibitor is a potassium salt of the compound of formula (I).

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the dual RAF/MEK inhibitor is IMM-1-104, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the dual RAF/MEK inhibitor is a compound of formula (II):
including pharmaceutically acceptable salts thereof, wherein:
Ring A is
R1, R2, R3, and R4 are each independently selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C-amido, optionally substituted N-amido, optionally substituted ester, optionally substituted sulfonyl, optionally substituted S-sulfonamido, optionally substituted N-sulfonamido, optionally substituted sulfonate, optionally substituted O-thiocarbamyl, optionally substituted N-thiocarbamyl, optionally substituted N-carbamyl, optionally substituted O-carbamyl, optionally substituted urea, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C10 heteroaryl, and L; R6 is selected from the group consisting of H, deuterium, hydroxyl, halogen, cyano, nitro, optionally substituted amino, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, and optionally substituted C2 to C6 alkynyl;
X is C(R5)2, CH(R5), CH2, —O—,
L is —Z1-Z2 or —Z1-Z2-Z3;
Z1, Z2, and Z3 are independently selected from the group consisting of —CH2—, —O—, —S—, S—O, —SO2—, C═O, —CO2—, —NO2, —NH—, —CH2CCH, —CH2CN, —NR5R5′, —NH(CO)—, —(CO)NH—, —(CO)NR5R5′—, —NH—SO2—, —SO2—NH—, —R5CH2—, —R5O—, —R5S—, R5—S—O, —R5SO2-, R5—C—O, —R5CO2—, —R5NH—, —R5NH(CO)—, —R5 (CO)NH—, —R5NH—SO2—, —R5SO2—NH—, —NHCH2CO—, —CH2R5—, —OR5—, —SR5—, S—O—R5, —SO2R5—, C—O—R5, —CO2R5—, —NHR5—, —NH(CO)R5—, —(CO)NHR5—, —NH—SO2R5—, —SO2—NHR5—, optionally substituted C1 to C6 alkyl, optionally substituted C3 to C8 cycloalkyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl, optionally substituted C3 to C10 heteroaryl, —CH2-(optionally substituted aryl), —CH2-(optionally substituted C3 to C8 cycloalkyl), and —CH2-(optionally substituted C3 to C10 heteroaryl); each R5 and R5′ are independently selected from H, deuterium, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C2 to C6 alkynyl, optionally substituted C3 to C8 carbocyclyl, optionally substituted C6 to C10 aryl, optionally substituted C3 to C8 heterocyclyl, and optionally substituted C3 to C10 heteroaryl; and
Y is CH2, NH, or O, with the proviso that R1 is not-O-pyrimidyl.

### Claim 8 (depends on 1, 2)

The method of any one of claims 1, 2, and 7, wherein the dual RAF/MEK inhibitor is a compound selected from the compound of Table I, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the dual RAF/MEK inhibitor is orally administered to the subject.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the dual RAF/MEK inhibitor is administered at least once a week.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dual RAF/MEK inhibitor is administered twice a week.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the dual RAF/MEK inhibitor is administered at a dose of 0.5 mg to about 10 mg per administration.

### Claim 13 (depends on 12)

The method of claim 12, wherein the dual RAF/MEK inhibitor is dosed at 3.2 mg per administration.

### Claim 14 (depends on 12)

The method of claim 12, wherein the dual RAF/MEK inhibitor is dosed at 4 mg per administration.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the dual RAF/MEK inhibitor is dosed as a cycle comprising administering the dual RAF/MEK inhibitor for three weeks and then not administering the dual RAF/MEK inhibitor for one week.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the KRAS G12D inhibitor is selected from the group consisting of KRAS G12D inhibitor (GenFleet), KRAS G12D degrader (Progenra), KRAS G12D inhibitor (Shenzhen Forward), KRAS G12D inhibitor (Abbisko), KRAS G12D inhibitor (Allist), KRAS G12D inhibitor (Anhorn), KRAS G12D inhibitor (Impact), TSL1502 (Tasly), KT-NIH anti-KRAS G12D mTCR PBL (Gilead), siG12D-LODER (Silenseed), siG12D inhibitor (Silenseed), Anocca-KRAS-G12D inhibitor (Anocca), KRAS ONCOlogue (Oncogenuity), Curve-KRAS G12D inhibitor (Curve Therapeutics), AST-KRAS G12D inhibitor (Allist Pharmaceuticals), VRTX144 (VRise Therapeutics), KRAS G12D inhibitor (Affini-T Therapeutics Inc), BPI-001 (BeyondSpring Inc), anti-KRAS G12D Monoclonal Antibody (LA Cell Inc), MRTX-1133 (Mirati Therapeutics Inc), NT-0300D (NeuBase Therapeutics Inc), PP-008 (Primary Peptides Inc), RMC-6236 (Revolution Medicines Inc), RMC-9805 (Revolution Medicines Inc), KRAS-G12D inhibitor (Arvinas Inc), anti-KRAS G12D Synthetic Peptide (Indi Molecular Inc), BBP-KRAS G12D inhibitor (BridgeBio Pharma Inc), ERAS-4 (Erasca Inc), JAB-22000 (Jacobio Pharmaceuticals Group Co Ltd), KRpep-2d (peptide) (Takeda Pharmaceutical Co Ltd), anti-KRAS G12D Monoclonal Antibodies (Oblique Therapeutics AB), Small Molecule KRAS G12D Inhibitors (Shenzhen Forward Pharmaceutical Co Ltd), Proteovant KRAS G12D inhibitor (Proteovant Therapeutics Inc), BIGPRO (Bi-functional ligand induced proteolysis) protein degrader (Anhorn Medicines Co Ltd), STX-XX KRAS G12D inhibitor (Seed Therapeutics Inc), and TPX-KRAS G12D inhibitor (Turning Point Therapeutics Inc), and pharmaceutically acceptable salts thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the KRAS G12D inhibitor is MRTX-1133, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the KRAS G12D inhibitor is orally administered to the subject.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the KRAS G12D inhibitor is intravenously administered to the subject.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the KRAS G12D inhibitor is subcutaneously administered to the subject.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the KRAS G12D inhibitor is administered once daily.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the KRAS G12D inhibitor is administered twice daily.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the KRAS G12D inhibitor is dosed at 1 mg to 2000 mg per administration.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the KRAS G12D inhibitor is dosed at 10 mg to 1000 mg per administration.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the KRAS G12D inhibitor is dosed at 100 mg to 1000 mg per administration.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein the cancer is pancreatic cancer, pancreatic ductal adenocarcinoma, gynecologic cancer (e.g., cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, endometrial cancer, or vulvar cancer), liver cancer, prostate cancer, mesothelioma, breast cancer, bladder cancer, melanoma, lung cancer, colorectal cancer, thyroid cancer, glioblastoma, or renal cancer.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the cancer lung cancer, colorectal cancer, or pancreatic cancer.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, wherein the lung cancer is non-small cell lung cancer.

### Claim 29 (depends on 26, 27, 28)

The method of claim any one of claims 26-28, wherein the lung cancer is metastatic non-small cell lung cancer.

### Claim 30 (depends on 26, 27)

The method of claim 26 or 27, wherein the cancer is colorectal cancer.

### Claim 31 (depends on 26, 27)

The method of claim 26 or 27, wherein the cancer is pancreatic cancer.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, further comprising administering to the subject an effective amount of a FAK inhibitor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the FAK inhibitor is defactinib, or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the FAK inhibitor is dosed at about 100 mg to about 1000 mg.

### Claim 35 (depends on 34)

The method of claim 34, wherein the FAK inhibitor is dosed at about 100 mg to about 400 mg per administration.

### Claim 36 (depends on 35)

The method of claim 35, wherein the FAK inhibitor is dosed at 200 mg per administration.

### Claim 37 (depends on 35)

The method of claim 35, wherein the FAK inhibitor is dosed at 400 mg per administration.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32-37, wherein the FAK inhibitor is administered once daily.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37)

The method of any one of claims 32-37, wherein the FAK inhibitor is administered twice daily.

### Claim 40 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 32-39, wherein the FAK inhibitor is dosed as a cycle, comprising administering the FAK inhibitor for three weeks and then not administering the FAK inhibitor for one week.

### Claim 41 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 32-40, wherein the FAK inhibitor is orally administered to the subject.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, further comprising administering to the subject an effective amount of an EGFR inhibitor.

### Claim 43 (depends on 42)

The method of claim 42, wherein the EGFR inhibitor is doxorubicin+erlotinib, futuximab+modotuximab, abivertinib (e.g., abivertinib maleate), ABP-1119, ABP-1130, afatinib (e.g., afatinib dimaleate), AG-101, AL-6802, almonertinib (e.g., almonertinib mesylate), AM-105, amelimumab, amivantamab, AMX-3009, APL-1898, ASK-120067, AST-2818, BBT-176, BDTX-189, BEBT-108, BEBT-109, BH-2922, BLU-4810, BMX-002, BO-1978, BPI-15086, BPI-7711, brigatinib, C-005, cetuximab, CK-101, CLM-29, CLM-3, CMAB-017, CR-13626, CSHEGF-29, D-0316, D2C7-IT+PVSRIPO, dabrafenib mesylate+panitumumab+trametinib dimethyl sulfoxide, dacomitinib, DBPR-112, depatuxizumab, DGD-1202, doxitinib (e.g., doxitinib mesylate), DZD-9008, EO-1001, epertinib, erlotinib (e.g., erlotinib hydrochloride), ES-072, FCN-411, FHND-9041, FLAG-001, FLAG-003, FmAb-2, GB-263, GC-1118A, gefitinib, GS-03+Osimertinib, HA-12128, HMPL-309, HMPL-813, HS-627, icotinib (e.g., icotinib hydrochloride), JMT-101, JRF-103, JZB-29, KBP-5209, KNP-501, KU-004, lapatinib (e.g., lapatinib ditosylate), larotinib, lazertinib, lifirafenib (e.g., lifirafenib maleate), MCLA-129, MCLA-158, MDC-22, mobocertinib, mRX-7, MTX-211, MVC-101, naquotinib (e.g., naquotinib mesylate), nazartinib (e.g., nazartinib mesylate), necitumumab, neratinib, nimotuzumab, NRC-2694, NT-004, NT-113, OBX-1012, olmutinib (e.g., olmutinib hydrochloride), osimertinib (e.g., osimertinib mesylate), panitumumab, PB-357, poziotinib, pyrotinib, QL-1105, QL-1203, RXDX-105, SAH-EJ1, sapitinib, SCT-200, selatinib (e.g., selatinib ditosilate), sirotinib, SKLB-1028, SKLB-1206, SPH-118811, SYN-004, TAS-6417, tesevatinib (e.g., tesevatinib tosylate), TGRX-360, tomuzotuximab, TQB-3804, UBP-1215, vandetanib, varlitinib, VRN-071918, VRN-6, WBP-297, WJ-13404, WSD-0922, XZP-5809, yinlitinib, YZJ-0318, ZNE-4, zorifertinib, ZR-2002, ZSP-0391, ORIC-114, DS-2087b, JS-111, LL-191, BI-4020, or BAY-2476568, or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 42, 43)

The method of claim 42 or 43, wherein the EGFR inhibitor is cetuximab, or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, further comprising administering to the subject an effective amount of an anti-PD-1 antibody.

### Claim 46 (depends on 45)

The method of claim 45, wherein the anti-PD-1 antibody is selected from the group consisting of balstilimab, camrelizumab, cemiplimab, dostarlimab, geptanolimab, nivolumab, pembrolizumab, penpulimab, pidilizumab, prolgolimab, retifanlimab, sasanlimab, serplulimab, serplulimab, sintilimab, spartalizumab, sulituzumab, tebotelimab, teripalimab, tislelizumab, toripalimab, toripalimab, zimberelimab, AMP-224, AMP-514, AT-16201, AVI-102, BAT-1308, BH-2950, BSI-050K01, CB-201, CYTO-101, DB-004, EX-105, EX-108, GNR-051, HAB-21, IBI-319, IBI-321, IKT-202, IMU-201, JS-201, LBL-006, LBL-024, LD-01, LQ-005, LQ-008, MD-402, OT-2, PE-0105, PF-07209960, PH-762, REGN-PD-1/XX, RO7121661, SAUG-1, SCT-110A, SG-001, SG001, SI-B003, SL-279137, SSI-361, STI-A1110, STM-418, Sym-021, TSR-075, TY101, Twist-PD-1, XmAb-TGFBR2, XmAb-YYCD28, XmAb20717, XmAb23104, YBL-006, YBL-019, and mDX-40.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, further comprising administering to the subject an effective amount of an anti-PD-L1 antibody.

### Claim 48 (depends on 47)

The method of claim 47, wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, durvalumab, envafolimab, socazolimab, sugemalimab, ABM-101, AP-505, APL-801, ATG-101, AVA-027, AUNP12, B-1961, BH-3120, BMS-986189, BPI-9220, BPI-9320, CA-170, CCX-559, CK-301, CS-17938, CTX-8371, CYTCDR-2, DB-003, DPDL-1E, DR-30207, DSP-105, DSP-502, EI-011, EI-014, EMB-08, ENN-101, ENN-102, GB-7003, Gensci-047, HB-0025, HB-0028, HB-0036, HBM-7015, IBI-327, IGM-7354, IKT-201, IMC-2101, IMC-2102, IMGS-002, IMM-2510, INBRX-105, JBI-426, JNB-809, JNB-809, JNB-813, JNB-813, KN-052, KN035, KY-1043, LP-008, LQ-002, LQ-004, LVGN-1673, LY-3434172, LYN-102, MCLA-145, MEDI-7526, PH-790, PM-1003, PRS-344, Q-1802, QL-301, QLS31901, RC98, SHR-1316, SHR-1701, SIM-236, SL-279252, SL-279258, SLSP-03, SNA-02, STT-01, TI-1007, TJ-L1C4, TJ-LID5, TJ-L1H3, TJ-L117, TJL-14B, TS1905, TST-005, TTXsiPDL-1, TXB-4BC3, VXM-10, YBL-007, YBL-008, YBL-009, YBL-013, YBL-016, and YBL-020.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, further comprising administering to the subject an effective amount of one or more chemotherapeutic agent.

### Claim 50 (depends on 49)

The method of claim 49, wherein the one or more chemotherapeutic agent is selected from the group consisting of folfirinox, gemcitabine, and paclitaxel.